Benzodioxane LTA4H Modulators for Age-Related Neuroinflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cognitive decline, motor impairment, neuroinflammation, and neurodegenerative disorders associated with aging have limited effectiveness in preventing and reversing these conditions.
Innovation Solution
Utilizing benzodioxane inhibitors of leukotriene A4 hydrolase (LTA4H) to modulate leukotriene production, thereby addressing cognitive impairment, age-related dementia, motor impairment, and neuroinflammation by targeting the LTA4H enzyme with benzodioxane compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for cognitive decline and neurodegenerative disorders are used, then treatment coverage is provided, but effectiveness in preventing and reversing conditions is limited
Solution Approach 1:
The patent changes the therapeutic parameter by targeting a different enzyme (LTA4H) compared to conventional treatments. By inhibiting LTA4H instead of traditional targets, the compound achieves both preventive and therapeutic effects with improved reliability in reversing cognitive decline and neurodegenerative conditions.
2Object-affected harmful factors
If LTA4H inhibition is used to reduce neuroinflammation, then neuroinflammatory pathways are suppressed, but potential side effects on other enzymatic functions may occur
Solution Approach 1:
The benzodioxane compound exhibits local quality by selectively inhibiting the LTA4H enzyme while preserving other enzymatic functions. The molecular structure is designed to fit specifically into the LTA4H active site, allowing targeted suppression of neuroinflammatory pathways without affecting other biological processes.
3Reliability
If benzodioxane compounds are administered to aged subjects, then cognitive function improves, but long-term safety data is limited
Solution Approach 1:
The patent applies preliminary action by testing the benzodioxane compounds in aged mouse models before human application. The preclinical studies in aged subjects provide early safety and efficacy data, allowing assessment of long-term effects and cognitive improvement potential before broader clinical deployment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The benzodioxane inhibitors demonstrate robust effects in improving cognition and reducing neuroinflammation in aged mice, offering potential therapeutic benefits for these age-related disorders.
Implementation Method 1
benzodioxane inhibitors of leukotriene A4 hydrolase (LTA4H) to modulate leukotriene production, thereby addressing cognitive impairment, age-related dementia, motor impairment, and neuroinflammation by targeting the LTA4H enzyme
Data Source
AI summary
This invention pertains to the prevention and treatment of aging-associated disease. The invention relates to the use of benzodioxane inhibitors of leukotriene production through modulation of leukotriene A4 hydrolase (“LTA4H”) to treat and/or prevent conditions associated with aging such as cognitive disorders, motor disorders, and neuroinflammation.